Table 1 Characteristics of the study population

Number

67

31

76

22

Age in years, mean (SD)

53.9 (17.4)

53.7 (12.6)

52.8 (16.8)

57.3 (12.7)

Gender, n (%)

   Male

40 (59.7)

21 (64.5)

46 (60.5)

15 (68.2)

   Female

27 (40.3)

10 (35.5)

30 (39.5)

7 (31.8)

Clinical diagnosis, n (%)

   Sepsis/severe infection

10 (14.9)

8 (25.8)

11 (14.5)

7 (31.8)

   Malignancies

21 (31.3)

12 (38.7)

22 (28.9)

10 (45.5)

   Hepatic failure

14 (20.9)

11 (35.5)

23 (30.3)

2 (9.1)

   Others^a

22 (32.8)

0 (0.0)

19 (25.0)

3 (13.6)

SOFA score

3.0 (0.0-4.0)

7.0 (5.0-8.0)^b

3.0 (0.0-5.0)

8.0 (5.0-8.8)^c

SAPS II

22.0 (11.0-35.0)

44.0 (25.3-66.5)^b

22.0 (12.0-37.0)

61.5 (27.5-74.5)^c

Platelets, × 10³/μL

164.0 (60.0-236.0)

51.0 (33-67.5)^b

133.5 (54.5-227.5)

56.5 (31.5-88.3)^c

Prothrombin time, seconds

15.0 (13.7-15.9)

22.0 (19.5-24.3)^b

15.0 (13.8-17.1)

21.6 (17.2-23.1)^c

D-dimer, μg/mL

2.0 (0.9-4.6)

7.0 (4.6-12.4)^b

2.0 (0.9-6.3)

5.5 (2.8-17.0)^c

Fibrinogen, mg/dL

338 (260-451)

199 (127-272)^b

303 (223-413)

272 (100-386)

Antithrombin, %

85 (60-112)

64 (32.5-81.5)^b

79.5 (59-107.5)

54.5 (32.0-83.8)^c

Protein C, %

67 (49-89)

27 (20-37.5)^b

59.0 (38.5-85.3)

34.5 (22.0-73.5)^c

Soluble tissue factor, pg/mL

68 (39-100)

98 (69-130)^b

68.7 (41.1-96.8)

116.5 (93.2-138.1)^c